LightDeck Diagnostics

LightDeck Diagnostics is a biotechnology and healthcare startup based in the United States, with a focus on revolutionizing healthcare through fast, accurate, and cost-effective diagnostic tests. Formerly known as MBio Diagnostics, the company's proprietary LightDeck® platform integrates advanced laser waveguide technology and novel materials to deliver lab-quality results in minutes, anywhere they are needed. The company's mission is to provide quality, quick, quantitative, and multiplex diagnostic tests without compromise, with the capability to run multiple related tests simultaneously. Their flagship product is an on-the-spot COVID-19 test, demonstrating the platform's versatility in addressing pressing healthcare needs. LightDeck Diagnostics has already made strides in veterinary diagnostics and environmental testing, leveraging the same technology. The company's relentless commitment to innovation and versatility has garnered considerable attention, with a grant investment from the National Institute of Food and Agriculture in June 14, 2022. LightDeck Diagnostics' vision aligns seamlessly with the current demand for rapid and accurate diagnostic testing, especially in the context of a global pandemic. Their technology, along with the recent investment, positions them as a noteworthy player in the biotechnology and healthcare industries. With the potential to expand their product portfolio and penetrate diverse markets, LightDeck Diagnostics stands as a promising investment opportunity for venture capitalists seeking impactful and innovative healthcare solutions. Learn more at LightDeckDx.com.